RevenanasBook a free audit

Expansion

BioMarin licenses Fabry disease ERT candidate in up to $475M deal with GC Biopharma and Hanmi

Biotech

Expansion

Key Facts

Signal Type

Expansion

Industry

Biotech

Companies

BioMarin, GC Biopharma, Hanmi Pharm, Amicus Therapeutics, Sanofi

Date

What Happened

BioMarin entered a licensing agreement with GC Biopharma and Hanmi Pharm to acquire worldwide rights (excluding South Korea) to HM15421/GC1134A, a phase 1/2 long-acting enzyme replacement therapy (ERT) for Fabry disease. The deal includes $70 million upfront and up to $405 million in development and commercial milestones, plus tiered royalties on net sales. The candidate is designed for subcutaneous injection once monthly, compared to current approved ERTs that require intravenous infusion every two weeks.

Who Is Affected

BioMarin’s Fabry disease team, including clinical development, regulatory, and commercial operations, will manage the new ERT program. The company already markets Galafold, an oral therapy generating $521.7M in 2025 from the Amicus acquisition, but Galafold is limited to patients with certain genetic mutations. The ERT could serve a broader patient population, increasing the addressable market. Competitors Sanofi, Chiesi, and Takeda have approved ERTs, while Amicus (now part of BioMarin) and other players remain relevant.

Market Impact

BioMarin’s pipeline expansion strengthens its position in the Fabry disease market, currently dominated by Sanofi’s Fabrazyme and Chiesi’s Elfabrio. The once-monthly subcutaneous profile could differentiate HM15421/GC1134A and capture patient preference over biweekly IV infusions. Key impacts include:

  • Increased R&D spend: BioMarin will invest in phase 1/2 and future trials, likely in the U.S., Argentina, and South Korea.
  • Competitive pressure: If successful, the ERT may erode market share from Sanofi, Chiesi, and Takeda, potentially reshaping treatment protocols.
  • Diagnosis rate focus: BioMarin aims to boost Fabry diagnosis rates to drive Galafold sales, which also supports the ERT’s future patient pool.

What to Watch

Monitor early phase 1/2 data on safety and efficacy, particularly the pharmacokinetic profile at three dose levels and kidney function outcomes over the 48-week study period. The enrollment pace in U.S. sites will signal trial execution quality. Additionally, watch for any regulatory alignment discussions or expansion into new geographies as BioMarin advances the candidate toward pivotal trials.

Related coverage

Get biotech signals in your CRM

FDA approvals and rejections, clinical trial results, pharma M&A, drug recalls, and funding rounds.

Book a 15 min call
Dominykas Rukas - Revenanas

More from this industry

    We can send changes like these to your own CRM, matched to the accounts your team sells to.

    Book a free audit

    Built in your tools.
    Run by your team.

    Tell us the commercial goal and where it gets stuck. We find the bottleneck with you and plan the first two week sprint from it.

    Dominykas Rukas, RevenanasDominykas RukasCo-founderBook a free audit
    • HubSpot partner badgeHubSpot partner
    • Enterprise Clay partner